| Specifications of the ACMG/AMP variant interpretation guidelines for germline TP53 variants C Fortuno, K Lee, M Olivier, T Pesaran, PL Mai, KC de Andrade, ... Human mutation 42 (3), 223-236, 2021 | 110 | 2021 |
| Variable population prevalence estimates of germline TP53 variants: A gnomAD‐based analysis KC de Andrade, MN Frone, T Wegman‐Ostrosky, PP Khincha, J Kim, ... Human mutation 40 (1), 97-105, 2019 | 90 | 2019 |
| The TP53 Database: transition from the International Agency for Research on Cancer to the US National Cancer Institute KC de Andrade, EE Lee, EM Tookmanian, CA Kesserwan, JJ Manfredi, ... Cell Death & Differentiation 29 (5), 1071-1073, 2022 | 68 | 2022 |
| Higher‐than‐expected population prevalence of potentially pathogenic germline TP53 variants in individuals unselected for cancer history KC de Andrade, L Mirabello, DR Stewart, E Karlins, R Koster, M Wang, ... Human mutation 38 (12), 1723-1730, 2017 | 61 | 2017 |
| XAF1 as a modifier of p53 function and cancer susceptibility EM Pinto, BC Figueiredo, W Chen, HCR Galvao, MN Formiga, ... Science advances 6 (26), eaba3231, 2020 | 43 | 2020 |
| Cancer incidence, patterns, and genotype–phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study KC de Andrade, PP Khincha, JN Hatton, MN Frone, T Wegman-Ostrosky, ... The lancet oncology 22 (12), 1787-1798, 2021 | 41 | 2021 |
| Fundamental immune–oncogenicity trade-offs define driver mutation fitness D Hoyos, R Zappasodi, I Schulze, Z Sethna, KC de Andrade, DF Bajorin, ... Nature 606 (7912), 172-179, 2022 | 30 | 2022 |
| Whole-body magnetic resonance imaging of Li-Fraumeni syndrome patients: observations from a two rounds screening of Brazilian patients D Paixão, MD Guimarães, KC De Andrade, AF Nóbrega, R Chojniak, ... Cancer Imaging 18, 1-8, 2018 | 27 | 2018 |
| Genome-wide association study identifies HLA-DPB1 as a significant risk factor for severe aplastic anemia SA Savage, M Viard, C O’huigin, W Zhou, M Yeager, SA Li, T Wang, ... The American Journal of Human Genetics 106 (2), 264-271, 2020 | 26 | 2020 |
| Frequency of thyroid carcinoma in Brazilian TP53 p. R337H carriers with Li Fraumeni syndrome MN da Cruz Formiga, KC De Andrade, LP Kowalski, MI Achatz Jama Oncology 3 (10), 1400-1402, 2017 | 22 | 2017 |
| Early-onset breast cancer patients in the South and Southeast of Brazil should be tested for the TP53 p.R337H mutation KC Andrade, KM Santiago, FP Fortes, LI Mambelli, AF Nóbrega, ... Genetics and molecular biology 39, 199-202, 2016 | 22 | 2016 |
| Prevalence of pathogenic/likely pathogenic variants in the 24 cancer genes of the ACMG Secondary Findings v2. 0 list in a large cancer cohort and ethnicity-matched controls J Kim, W Luo, M Wang, T Wegman-Ostrosky, MN Frone, JJ Johnston, ... Genome medicine 10, 1-9, 2018 | 20 | 2018 |
| Frequency of pathogenic germline variants in cancer-susceptibility genes in the Childhood Cancer Survivor Study J Kim, M Gianferante, DM Karyadi, SW Hartley, MN Frone, W Luo, ... JNCI Cancer Spectrum 5 (2), pkab007, 2021 | 16 | 2021 |
| Pathogenic germline IKZF1 variant alters hematopoietic gene expression profiles SA Brodie, PP Khincha, N Giri, AJ Bouk, M Steinberg, J Dai, L Jessop, ... Molecular Case Studies 7 (4), a006015, 2021 | 7 | 2021 |
| Landscape of Germline Genetic Variants in AGT, MGMT, and TP53 in Mexican Adult Patients with Astrocytoma JA Carlos-Escalante, L Gomez-Flores-Ramos, X Bian, ... Cellular and Molecular Neurobiology 41 (6), 1285-1297, 2021 | 7 | 2021 |
| Variant Curation Expert Panel.(2021) C Fortuno, K Lee, M Olivier, T Pesaran, PL Mai, KC de Andrade, ... Specifications of the ACMG/AMP variant interpretation guidelines for …, 0 | 6 | |
| Specifications of the ACMG C Fortuno, K Lee, M Olivier AMP variant interpretation guidelines for germline TP53 variants. medRxiv 25, 2020 | 3 | 2020 |
| Genome-first approach of the prevalence and cancer phenotypes of pathogenic or likely pathogenic germline TP53 variants KC de Andrade, NT Strande, J Kim, JS Haley, JN Hatton, MN Frone, ... Human Genetics and Genomics Advances 5 (1), 2024 | 1 | 2024 |
| Multiple germline events contribute to cancer development in patients with Li-Fraumeni syndrome V Subasri, N Light, N Kanwar, J Brzezinski, P Luo, JR Hansford, ... Cancer research communications 3 (5), 738-754, 2023 | 1 | 2023 |
| Spectrum and incidence of skin cancer among individuals with Li-Fraumeni syndrome JN Hatton, MR Sargen, MN Frone, KC de Andrade, SA Savage, ... The Journal of investigative dermatology 142 (9), 2534, 2022 | 1 | 2022 |
